SELLAS Life Sciences Group, Inc. Common Stock

SELLAS trades at a striking 30.81% short float while sitting at its 52-week high, creating a potent setup for volatility. The RSI of 72.9 signals extreme overbought conditions, yet the company carries no meaningful earnings (n/a P/E), suggesting this $1.7B valuation rests entirely on speculative momentum rather than profitability. With three-in-ten shares sold short and the stock already at year-long peaks, the combination hints at potential squeeze dynamics—though the overbought reading and lack of earnings fundamentals equally suggest exhaustion risk. This is a setup defined by technical extremes and sentiment extremes, not business substance.